16 results on '"Petri, Francesco"'
Search Results
2. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
- Author
-
Castelnuovo, Augusto Di, Costanzo, Simona, Antinori, Andrea, Berselli, Nausicaa, Blandi, Lorenzo, Bruno, Raffaele, Cauda, Roberto, Guaraldi, Giovanni, Menicanti, Lorenzo, My, Ilaria, Parruti, Giustino, Patti, Giuseppe, Perlini, Stefano, Santilli, Francesca, Signorelli, Carlo, Spinoni, Enrico, Stefanini, Giulio G., Vergori, Alessandra, Ageno, Walter, Agodi, Antonella, Aiello, Luca, Agostoni, Piergiuseppe, Moghazi, Samir Al, Astuto, Marinella, Aucella, Filippo, Barbieri, Greta, Bartoloni, Alessandro, Bonaccio, Marialaura, Bonfanti, Paolo, Cacciatore, Francesco, Caiano, Lucia, Cannata, Francesco, Carrozzi, Laura, Cascio, Antonio, Ciccullo, Arturo, Cingolani, Antonella, Cipollone, Francesco, Colomba, Claudia, Crosta, Francesca, Pra, Chiara Dal, Danzi, Gian Battista, D'Ardes, Damiano, Donati, Katleen de Gaetano, Giacomo, Paola Del, Gennaro, Francesco Di, Di Tano, Giuseppe, D'Offizi, Giampiero, Filippini, Tommaso, Fusco, Francesco Maria, Gentile, Ivan, Gialluisi, Alessandro, Gini, Giancarlo, Grandone, Elvira, Grisafi, Leonardo, Guarnieri, Gabriella, Lamonica, Silvia, Landi, Francesco, Leone, Armando, Maccagni, Gloria, Maccarella, Sandro, Madaro, Andrea, Mapelli, Massimo, Maragna, Riccardo, Marra, Lorenzo, Maresca, Giulio, Marotta, Claudia, Mastroianni, Franco, Mazzitelli, Maria, Mengozzi, Alessandro, Menichetti, Francesco, Meschiari, Marianna, Minutolo, Filippo, Montineri, Arturo, Mussinelli, Roberta, Mussini, Cristina, Musso, Maria, Odone, Anna, Olivieri, Marco, Pasi, Emanuela, Petri, Francesco, Pinchera, Biagio, Pivato, Carlo A., Poletti, Venerino, Ravaglia, Claudia, Rinaldi, Massimo, Rognoni, Andrea, Rossato, Marco, Rossi, Ilaria, Rossi, Marianna, Sabena, Anna, Salinaro, Francesco, Sangiovanni, Vincenzo, Sanrocco, Carlo, Scorzolini, Laura, Sgariglia, Raffaella, Simeone, Paola Giustina, Spinicci, Michele, Trecarichi, Enrico Maria, Venezia, Amedeo, Veronesi, Giovanni, Vettor, Roberto, Vianello, Andrea, Vinceti, Marco, Vocciante, Laura, De Caterina, Raffaele, and Iacoviello, Licia
- Published
- 2020
- Full Text
- View/download PDF
3. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
- Author
-
Di Castelnuovo, Augusto, Costanzo, Simona, Antinori, Andrea, Berselli, Nausicaa, Blandi, Lorenzo, Bonaccio, Marialaura, Cauda, Roberto, Gialluisi, Alessandro, Guaraldi, Giovanni, Menicanti, Lorenzo, Mennuni, Marco, Mussinelli, Roberta, My, Ilaria, Parruti, Giustino, Patti, Giuseppe, Perlini, Stefano, Santilli, Francesca, Signorelli, Carlo, Stefanini, Giulio G., Vergori, Alessandra, Abete, Pasquale, Ageno, Walter, Agostoni, Piergiuseppe, Aiello, Luca, Al Moghazi, Samir, Arboretti, Rosa, Aucella, Filippo, Barbieri, Greta, Barchitta, Martina, Bartoloni, Alessandro, Bonfanti, Paolo, Cacciatore, Francesco, Caiano, Lucia, Carrozzi, Laura, Cascio, Antonio, Castiglione, Giacomo, Cianfrone, Stefania, Ciccullo, Arturo, Cingolani, Antonella, Cipollone, Francesco, Colomba, Claudia, Colombo, Crizia, Cozzi, Ottavia, Crisetti, Annalisa, Crosta, Francesca, Danzi, Gian Battista, D'Ardes, Damiano, de Gaetano Donati, Katleen, Di Gennaro, Francesco, Di Tano, Giuseppe, D'Offizi, Gianpiero, Fusco, Francesco Maria, Gentile, Ivan, Graziani, Emauele, Guarnieri, Gabriella, Larizza, Giovanni, Leone, Armando, Lio, Veronica, Lucia, Mothanje Barbara, Maccagni, Gloria, Madaro, Ferruccio, Maitan, Stefano, Mancarella, Sandro, Manuele, Rosa, Mapelli, Massimo, Maragna, Riccardo, Marcucci, Rossella, Maresca, Giulio, Marongiu, Silvia, Marotta, Claudia, Marra, Lorenzo, Mastroianni, Franco, Mazzitelli, Maria, Mengozzi, Alessandro, Menichetti, Francesco, Meschiari, Marianna, Milic, Jovana, Minutolo, Filippo, Molena, Beatrice, Mussini, Cristina, Musso, Maria, Odone, Anna, Olivieri, Marco, Palimodde, Antonella, Pasi, Emanuela, Pesavento, Raffaele, Petri, Francesco, Pinchera, Biagio, Pivato, Carlo A., Poletti, Venerino, Ravaglia, Claudia, Rossato, Marco, Rossi, Marianna, Sabena, Anna, Salinaro, Francesco, Sangiovanni, Vincenzo, Sanrocco, Carlo, Scoppettuolo, Giancarlo, Scorzolini, Laura, Sgariglia, Raffaella, Simeone, Paola Giustina, Trecarichi, Enrico Maria, Vettor, Roberto, Vianello, Andrea, Vinceti, Marco, Virano, Alexandra, Vocciante, Laura, De Caterina, Raffaele, and Iacoviello, Licia
- Published
- 2020
- Full Text
- View/download PDF
4. Plasma Microbial Cell-free DNA Next-generation Sequencing Can Be a Useful Diagnostic Tool in Patients With Osteoarticular Infections.
- Author
-
Petri, Francesco, Mahmoud, Omar K, Ranganath, Nischal, Zein, Said El, Saleh, Omar Abu, Berbari, Elie F, and Fida, Madiha
- Subjects
- *
CELL-free DNA , *SHOTGUN sequencing , *NUCLEOTIDE sequencing , *DNA sequencing , *DIAGNOSIS - Abstract
Background Recent advances in shotgun metagenomic sequencing (sMGS) for detecting microbial cell-free DNA (mcfDNA) in peripheral blood have shown promise across various patient populations. This study evaluates the application of sMGS for diagnosing osteoarticular infections (OAIs), a condition with significant diagnostic challenges. Methods We conducted a retrospective analysis on 73 patients suspected of OAIs at the Mayo Clinic from 2019 to 2023, incorporating mcfDNA sMGS (Karius test [KT]) into their diagnostic evaluation. We categorized the clinical impact of KT on OAI diagnoses and management into 4 distinct outcomes. (1) KT was able to confirm an established diagnosis, (2) KT supported noninfectious diseases diagnosis, (3) KT established an unsuspected diagnosis, (4) KT did not add relevant information. Results In our cohort, KT was performed in 73 patients. Among the infected individuals, KT yielded positive results in 22 of 43 (51.2%) cases. Of these 22 cases, 11 (50%) showed agreement with conventional diagnostic workup, whereas in 5 (22.7%) cases, the KT established an unsuspected diagnosis. Native vertebral osteomyelitis diagnosis (P <.001) or OAIs with concomitant presence of endocarditis or endovascular infection (P =.005) were statistically associated with a definite, probable, or possible diagnostic certainty of KT result. Conclusions In complex OAIs, KT enhanced diagnostic accuracy by 11.6%, proving especially beneficial in diagnosing native vertebral osteomyelitis and infections with concurrent endocarditis or endovascular complications. Our findings underscore the utility of KT in the diagnostic workflow for challenging OAI cases, potentially altering clinical management for a significant subset of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. It is time for a unified definition of native vertebral osteomyelitis: a framework proposal.
- Author
-
Petri, Francesco, Mahmoud, Omar, El Zein, Said, Nassr, Ahmad, Freedman, Brett A., Verdoorn, Jared T., Tande, Aaron J., and Berbari, Elie F.
- Published
- 2024
- Full Text
- View/download PDF
6. Phage Therapy for Cardiac Implantable Electronic Devices and Vascular Grafts: A Targeted Literature Review.
- Author
-
Passerini, Matteo, Petri, Francesco, and Suh, Gina A.
- Subjects
VASCULAR grafts ,LITERATURE reviews ,ARTIFICIAL implants ,ELECTRONIC equipment ,HEART assist devices ,BACTERIOPHAGES - Abstract
Infections of cardiac implantable electronic devices (CIEDs) and vascular grafts are some of the most dreaded complications of these otherwise life-saving devices. Many of these infections are not responsive to conventional treatment, such as systemic antibiotics and surgical irrigation and debridement. Therefore, innovative strategies to prevent and manage these conditions are warranted. Among these, there is an increasing interest in phages as a therapeutical option. In this review, we aim to collect the available evidence for the clinical application of phage therapy for CIED and vascular graft infections through literature research. We found 17 studies for a total of 34 patients. Most of the indications were left ventricular assist device (LVAD) (n = 20) and vascular graft infections (n = 7). The bacteria most often encountered were Staphylococcus aureus (n = 18) and Pseudomonas aeruginosa (n = 16). Clinical improvements were observed in 21/34 (61.8%) patients, with microbiological eradication in 18/21 (85.7%) of them. In eight cases, an adverse event related to phage therapy was reported. Phage therapy is a promising option for difficult-to-treat CIED and vascular graft infections by means of an individualized approach. Clinical trials and expanded access programs for compassionate use are needed to further unveil the role of phage therapy in clinical application. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Rifampin Based Therapy for Patients With Staphylococcus aureus Native Vertebral Osteomyelitis: A Systematic Review and Meta-analysis.
- Author
-
Zein, Said El, Berbari, Elie F, Passerini, Matteo, Petri, Francesco, Maamari, Julian, Murad, M Hassan, Sendi, Parham, and Tande, Aaron J
- Subjects
MEDICAL databases ,META-analysis ,MEDICAL information storage & retrieval systems ,CONFIDENCE intervals ,VERTEBRAE ,SYSTEMATIC reviews ,STAPHYLOCOCCUS aureus ,OSTEOMYELITIS ,RESEARCH funding ,RIFAMPIN ,MEDLINE ,DISCITIS - Abstract
Background Native vertebral osteomyelitis (NVO) caused by Staphylococcus aureus is associated with high risk of treatment failure and increased morbidity. The role of rifampin-based therapy for the treatment of this condition is controversial. The goal of this systematic review and meta-analysis is to explore the efficacy and safety of rifampin-based therapy for the treatment of S. aureus NVO. Methods We searched Cochrane, Embase, Medline, Scopus, and Web of Science databases for studies published up to May 2023, focusing on adults with NVO treated with or without rifampin-containing regimens. A random-effects model meta-analysis estimated relative risks and risk difference with 95% confidence intervals (CI). Results Thirteen studies (2 randomized controlled trials and 11 comparative cohort studies), comprising 244 patients with S. aureus NVO who received rifampin and 435 who did not, were analyzed. Meta-analysis showed that rifampin-based regimens were associated with lower risk of clinical failure (risk difference, −14%; 95% CI, −19% to −8%; P <.001; I
2 = 0%; relative risk, 0.58; 95% CI,.37–.92, P =.02, I2 = 21%). Only 1 study reported on adverse events. All studies had a high or uncertain risk of bias, and the certainty of evidence was rated as very low. Conclusions Adjunctive rifampin therapy might be associated with lower risk of S. aureus NVO treatment failure; however, the low certainty of evidence precludes drawing definitive conclusions that would alter clinical practice. A randomized trial is necessary to corroborate these findings. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
8. High prevalence of high‐risk HPV genotypes in individuals attending an infectious diseases clinic from 2018 to 2022 in Milan, Italy.
- Author
-
Rizzo, Alberto, Moschese, Davide, Salari, Federica, Giacomelli, Andrea, Morelli, Loriana, Cossu, Maria Vittoria, Fusetti, Chiara, Petri, Francesco, Casalini, Giacomo, Poloni, Andrea, Lazzarin, Samuel, Gori, Andrea, Antinori, Spinello, Gismondo, Maria Rita, Lombardi, Alessandra, and Rizzardini, Giuliano
- Subjects
ANAL cancer ,HUMAN papillomavirus ,GENITAL warts ,COMMUNICABLE diseases ,SEXUALLY transmitted diseases ,GENOTYPES - Abstract
Human papillomavirus (HPV) is the most common sexually transmitted infection, linked to several types of lesions. HPV, specifically HPV 16, accounts for most of anal cancer cases. In this study, we evaluated the proportion of samples tested positive for HPV and characterized genotypes distribution in anal specimens collected from individuals at risk of anal HPV infection attending from 2018 to 2022 a large Infectious Diseases Department in Italy. The presence of HPV DNA was investigated through a commercial kit detecting 12 HR‐HPV, 8 probable/possible HR‐HPV, and 8 LR‐HPV genotypes. Among 1514 samples, 84% (1266/1514) resulted positive for any type of HPV. The prevalence of high‐risk HPV types remained high during all the years of the study period, from 2018 to 2022, ranging from 65% to 73%. Most of HR‐HPV, LR‐HPV and HPV 16 positive samples were collected from men >45 years. HPV 16 was also the most frequent type in men and women. We did not observe significant variations between years in detection of HR‐HPV, instead of LR‐HPV, that significantly decreased. In conclusion, the high prevalence of oncogenic HPV genotypes underlines the necessity of clear anal HPV screening guidelines and, along with frequent HR‐HPV coinfections, reinforces the urge to intensify the anti‐HPV vaccination campaign. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
- Author
-
Cattaneo, Dario, Fusi, Marta, Colaneri, Marta, Fusetti, Chiara, Genovese, Camilla, Giorgi, Riccardo, Matone, Maddalena, Merli, Stefania, Petri, Francesco, and Gori, Andrea
- Subjects
DRUG monitoring ,PROSTHESIS-related infections ,LOG-linear models ,SKIN infections - Abstract
Dalbavancin is a long-acting lipoglycopeptide that is registered for the treatment of acute bacterial skin and skin structure infections, and it is also increasingly used for infections that require prolonged antibiotic treatment. Here, we present the results from the first 2 years of a service set up in December 2021 for the therapeutic drug monitoring (TDM) of dalbavancin in clinical settings. In particular, we compared the trough concentration (Cmin) to maximum concentration (Cmax) in patients with osteoarticular infections receiving prolonged treatment with dalbavancin. Log-linear regression models were used to estimate the timing of dalbavancin administration with the goal of maintaining Cmin concentrations of >8 mg/L in the two TDM-based strategies. From December 2021 to November 2023, 366 TDMs of dalbavancin from 81 patients were performed. The Cmin and Cmax concentrations of dalbavancin ranged from 4.1 to 70.5 mg/L and from 74.9 to 995.6 mg/L, respectively. With log-linear regression models, we estimated that each injection should be administered every 42–48 days to maintain the Cmin concentrations. Out of the 81 patients, 37 received at least three doses of dalbavancin for the treatment of osteoarticular infections. Despite there being no significant differences in the days of dalbavancin treatment (130 ± 97 versus 106 ± 102 days), the patients in the Cmax-based TDM group received a significantly lower number of dalbavancin injections (5.2 ± 1.8 versus 7.3 ± 2.6 injections, p = 0.005), and they were administered over a longer period of time (40 ± 10 versus 29 ± 14 days, p = 0.013) than in the Cmin-based TDM group. In conclusion, Cmax-based TDM was associated with a significant reduction in the inter-individual variability of dalbavancin concentrations and lower drug dosing frequency than those of Cmin-based TDM. This approach could, therefore, favor a more rational and targeted use of dalbavancin in patients requiring prolonged treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Comorbidity assessment as predictor of short and long-term mortality in elderly patients with hemodynamically stable acute pulmonary embolism
- Author
-
Polo Friz, Hernan, Corno, Valeria, Orenti, Annalisa, Buzzini, Chiara, Crivellari, Chiara, Petri, Francesco, Polo Friz, Melisa, Punzi, Veronica, Teruzzi, Daniela, Cavalieri d’Oro, Luca, Giannattasio, Cristina, Vighi, Giuseppe, Cimminiello, Claudio, and Boracchi, Patrizia
- Published
- 2017
- Full Text
- View/download PDF
11. Recurrent and fatal diarrhea caused by Cystoisospora belli in a man with HIV infection.
- Author
-
Petri, Francesco, Angeli, Elena, Tedesco, Michela, Maconi, Giovanni, Pellegrinelli, Alessandro, Grande, Romualdo, and Rizzardini, Giuliano
- Abstract
Cystoisospora belli causes intestinal infection in immunocompromised hosts, including human immunodeficiency viruses (HIV)-positive patients, especially from tropical and sub-tropical areas, with watery and recurrent diarrhea, leading in advanced cases to malabsorption and death. Microbiological diagnosis is limited by intermittent or low shedding of oocysts in stool; therefore, endoscopy may be necessary to identify the pathogen in histological samples. Trimethoprim-sulfamethoxazole (TMP-SMX) represents the treatment of choice, and alternative agents are used in recurrences, but limited efficacy is described. Here, we present recently observed case of severe and fatal infection due to C. belli in a HIV-positive 40-year-old man from Brazil, revealing several limitations in diagnosis and therapy, which need to be investigated further. In particular, it is still not clear how the infection persisted over time leading to malabsorption, kidney injury, and subsequent death, even if a reasonable immune reconstitution was demonstrated. Additionally, we investigated what mechanisms might cause, whether failure of recovery of the immune response specifically to C. belli, drug malabsorption, resistance to TMP-SMX, sequestration into lymphoid tissue, or co-presence of visceral untreated Kaposi sarcoma. Also, the appropriate dosage and way of administration of the best therapeutic regimen were examined, since there is a lack of literature on these issues. Globalization and wider use of immunosuppressive therapies underline the importance of maintaining adequate awareness, also in HIV-negative and non-immigrant populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Comorbidity Burden and Suboptimal Immunological Responses to Coronavirus Disease 2019 Vaccination in People Living with Human Immunodeficiency Virus.
- Author
-
Cossu, Maria Vittoria, Mileto, Davide, Giacomelli, Andrea, Oreni, Letizia, Bracchitta, Fiorenza, Pellicciotta, Martina, Salari, Federica, Petri, Francesco, Meraviglia, Paola, Antinori, Spinello, Rizzardini, Giuliano, and Ridolfo, Anna Lisa
- Subjects
COVID-19 ,HIV ,COVID-19 pandemic ,MEDICAL personnel ,VACCINATION ,CORONAVIRUS diseases - Abstract
To theEditor - We were very interested to read the article by Lapointe et al [[1]] regarding the ability of people with human immunodeficiency virus (HIV) (PWH) to mount an efficient antibody response to coronavirus disease 2019 (COVID-19) vaccine. After 7 months, the PWH had a mean (SD) anti-S IgG titer of 309 (216) BAU/mL, whereas the mean anti-S IgG titers of the HCWs at 4 and 10 months were 1218 (649) and 361 (368) BAU/mL, respectively. Anti-S1 spike protein (anti-S) immunoglobulin (Ig) G antibody titers in people with human immunodeficiency virus (PWH) and healthy healthcare workers (HCWs) over time. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
13. Mortality rates among COVID-19 patients hospitalised during the first three waves of the epidemic in Milan, Italy: A prospective observational study.
- Author
-
Giacomelli, Andrea, Ridolfo, Anna Lisa, Pezzati, Laura, Oreni, Letizia, Carrozzo, Giorgia, Beltrami, Martina, Poloni, Andrea, Caloni, Beatrice, Lazzarin, Samuel, Colombo, Martina, Pozza, Giacomo, Pagano, Simone, Caronni, Stefania, Fusetti, Chiara, Gerbi, Martina, Petri, Francesco, Borgonovo, Fabio, D'Aloia, Fabiana, Negri, Cristina, and Rizzardini, Giuliano
- Subjects
COVID-19 ,DEATH rate ,LONGITUDINAL method ,SEX (Biology) ,SCIENTIFIC observation ,HOSPITAL mortality ,COMORBIDITY - Abstract
Introduction: This paper describes how mortality among hospitalised COVID-19 patients changed during the first three waves of the epidemic in Italy. Methods: This prospective cohort study used the Kaplan-Meier method to analyse the time-dependent probability of death of all of the patients admitted to a COVID-19 referral centre in Milan, Italy, during the three consecutive periods of: 21 February-31 July 2020 (first wave, W1), 1 August 2020–31 January 2021 (second wave, W2), and 1 February-30 April 2021 (third wave, W3). Cox models were used to examine the association between death and the period of admission after adjusting for age, biological sex, the time from symptom onset to admission, disease severity upon admission, obesity, and the comorbidity burden. Results: Of the 2,023 COVID-19 patients admitted to our hospital during the study period, 553 (27.3%) were admitted during W1, 838 (41.5%) during W2, and 632 (31.2%) during W3. The crude mortality rate during W1, W2 and W3 was respectively 21.3%, 23.7% and 15.8%. After adjusting for potential confounders, hospitalisation during W2 or W3 was independently associated with a significantly lower risk of death than hospitalisation during W1 (adjusted hazard ratios [AHRs]: 0.75, 95% confidence interval [CI] 0.59–0.95, and 0.58, 95% CI 0.44–0.77). Among the patients aged >75 years, there was no significant difference in the probability of death during the three waves (AHRs during W2 and W3 vs W1: 0.93, 95% CI 0.65–1.33, and 0.88, 95% CI 0.59–1.32), whereas those presenting with critical disease during W2 and W3 were at significantly lower risk of dying than those admitted during W1 (AHRs 0.61, 95% CI 0.43–0.88, and 0.44, 95% CI 0.28–0.70). Conclusions: Hospitalisation during W2 and W3 was associated with a reduced risk of COVID-19 death in comparison with W1, but there was no difference in survival probability in patients aged >75 years. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Comorbidity burden conditions the prognostic performance of D-dimer in elderly patients with acute pulmonary embolism.
- Author
-
Polo Friz, Hernan, Pezzetti, Valentina, Orenti, Annalisa, Caleffi, Alessandro, Corno, Valeria, Crivellari, Chiara, Petri, Francesco, Polo Friz, Melisa, Punzi, Veronica, Teruzzi, Daniela, d'Oro, Luca Cavalieri, Giannattasio, Cristina, Vighi, Giuseppe, Cimminiello, Claudio, and Boracchi, Patrizia
- Abstract
Introduction: The prognostic accuracy of D-dimer for risk assessment in acute Pulmonary Embolism (APE) patients may be hampered by comorbidities. We investigated the impact of comorbidity burden (CB) by using the Charlson Comorbidity Index (CCI), on the prognostic ability of D-dimer to predict 30 and 90-day mortality in hemodynamically stable elderly patients with APE.Methods: All patients aged >65 years with normotensive APE, consecutively evaluated in the Emergency Department since 2010 through 2014 were included in this retrospective cohort study. Area under the curve (AUC) and ½ Net Reclassification Improvement (NRI) were calculated.Results: Study population: 162 patients, median age: 79.2 years. The optimal cut-off value of CCI score for predicting mortality was ≤1 (Low CB) and >1 (High CB), AUC = 0.786. Higher levels of D-dimer were associated with an increased risk death at 30 (HR = 1.039, 95%CI:1.000-1.080, p = 0.049) and 90 days (HR = 1.039, 95%CI:1.009-1.070, p = 0.012). When added to simplified Pulmonary Embolism Severity Index (sPESI) score, D-dimer increased significantly the AUC for predicting 30-day mortality in Low CB (AUC = 0.778, 95%CI:0.620-0.937, ½NRI = 0.535, p = 0.015), but not in High CB patients (AUC = 0.634, 95%CI:0.460-0.807, ½ NRI = 0.248, p = 0.294). Similarly, for 90-day mortality D-dimer increased significantly the AUC in Low CB (AUC = 0.786, 95%CI:0.643-0.929, ½NRI = 0.424, p-value = 0.025), but not in High CB patients (AUC = 0.659, 95%CI:0.541-0.778, ½NRI = 0.354, p-value = 0.165).Conclusion: In elderly patients with normotensive APE, comorbidities condition the prognostic performance of D-dimer, which was found to be a better predictor of death in subjects with low CB. These results support multimarker strategies for risk assessment in this population. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. Simultaneous validation of the SunTech CT40 automated blood pressure measurement device by the 1993 British Hypertension Society protocol and the Association for the Advancement of Medical Instrumentation/International Organization for Standardization 81060-2: 2013 standard.
- Author
-
Friz, Hernan Polo, Punzi, Veronica, Petri, Francesco, Orlandi, Riccardo, Maggiolini, Daniele, Friz, Melisa Polo, Primitz, Laura, Vighi, Giuseppe, Polo Friz, Hernan, and Polo Friz, Melisa
- Published
- 2017
- Full Text
- View/download PDF
16. Remdesivir in moderate to severe COVID-19: A matter of time?
- Author
-
Bonazzetti, Cecilia, Giacomelli, Andrea, Pavia, Martina, Fusetti, Chiara, Gerbi, Martina, Petri, Francesco, Poloni, Andrea, Oreni, Letizia, Ridolfo, Anna Lisa, and Antinori, Spinello
- Subjects
- *
COVID-19 , *REMDESIVIR - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.